個性化醫學(ISSN 1741-0541)將最近基因組學、遺傳學和蛋白質組學的進展轉化為臨床應用。該雜志為所有參與者提供了一個綜合論壇，包括學術和臨床研究人員、制藥公司、監管機構、醫療管理組織、患者組織和醫療行業的其他組織。個性化醫療通過提供一個專家評論和分析的平臺，幫助這些團體塑造醫學的未來。該雜志涉及個性化醫療的科學、商業和政策問題，包括新聞和觀點，對新生物標志物的最新認識，簡明的評論和分析，會議巡回報告和完整的綜述文章。提交給個性化醫療的文章必須經過嚴格的同行審查。討論的主題包括:分子診斷的進展;生物芯片/微陣列技術;針對特定遺傳和免疫靶點的生物療法或疫苗方法;個性化醫療的成本效益問題;個性化醫療倫理;個性化醫療對醫療保健和制藥行業的影響基于藥物基因組學、藥物基因學和藥物蛋白質組學的個性化藥物發展的最新概念的影響將遺傳分析納入臨床試驗方法;診斷與治療相結合;藥物不良反應及安全性預測治療監測。

Personalized Medicine (ISSN 1741-0541) translates recent genomic, genetic and proteomic advances into the clinical context. The journal provides an integrated forum for all players involved - academic and clinical researchers, pharmaceutical companies, regulatory authorities, healthcare management organizations, patient organizations and others in the healthcare community. Personalized Medicine assists these parties to shape the future of medicine by providing a platform for expert commentary and analysis. The journal addresses scientific, commercial and policy issues in Personalized Medicine and includes news and views, current awareness regarding new biomarkers, concise commentary and analysis, reports from the conference circuit and full review articles. Articles submitted to Personalized Medicine are subject to rigorous peer review. Topics addressed include: Advances in molecular diagnostics; Biochip/microarray technologies; Biological therapies or vaccine approaches at specific genetic and immunologic targets; Cost-benefit issues for personalized medicine; Ethics in personalized medicine; Impact of personalized medicine on healthcare and the pharmaceutical industry; Impact of the latest concepts of development of personalized medicine based on pharmacogenomics, pharmacogenetics and pharmacoproteomics; Incorporation of genetic analysis in clinical trials methodology; Integration of diagnosis with therapy; Prediction of adverse reactions of drugs and drug safety; Treatment monitoring.